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Epigenetic response of imprinted domains
during carcinogenesis
Corey L. Bretz1, Ingeborg M. Langohr2 and Joomyeong Kim1*
Abstract
Background: Imprinted domains have been identified as targets for aberrant DNA methylation during
carcinogenesis, but it remains unclear when these epigenetic alterations occur and how they contribute to tumor
progression. Epigenetic instability at key cis-regulatory elements within imprinted domains can concomitantly
activate proto-oncogenes and turn off tumor suppressor genes. Thus, to further characterize the epigenetic
response of imprinted domains during carcinogenesis, we compared the stability of DNA methylation at a variety
of cis-regulatory elements within imprinted domains in two fundamentally different mouse tumors, benign and
malignant, induced by the KrasG12D mutation.
Results: We report that imprinted domains remain stable in benign processes but are highly susceptible to
epigenetic alterations in infiltrative lesions. The preservation of DNA methylation within imprinted domains in
benign tumors throughout their duration suggests that imprinted genes are not involved with the initiation of
carcinogenesis or the growth of tumors. However, the frequent detection of DNA methylation changes at
imprinting control regions in infiltrative lesions suggest that imprinted genes are associated with tumor cells
gaining the ability to defy tissue boundaries.
Conclusion: Overall, this study demonstrates that imprinted domains are targeted for DNA hypermethylation when
benign tumor cells transition to malignant. Thus, monitoring DNA methylation within imprinted domains may be
useful in evaluating the progression of neoplasms.
Keywords: DNA methylation, Genomic imprinting, Imprinting control regions, Imprinted genes, Cancer,
Carcinogenesis, Squamous papilloma, T cell lymphoma
Background
1Imprinted genes are mainly expressed from a single al-
lele based upon the allele’s parental origin [1]. Thus far,
there have been just over 100 imprinted genes identified
by conventional methodology; however, a far greater
number of imprinted genes may exist due to recent data
obtained by implementing modern whole-transcriptome
sequencing technologies [2, 3]. Nevertheless, the well-
known imprinted genes are clustered in discrete chromo-
somal domains, which often contain a differentially meth-
ylated master cis-regulatory element termed an imprinting
control region (ICR) [1, 4, 5]. ICRs are accompanied by
other cis-regulatory elements such as enhancers and dif-
ferentially methylated promoters that act synergistically
within their respective imprinted domain to elegantly con-
trol imprinted gene dosage [1, 6]. While DNA methylation
is transient among the other cis-regulatory elements de-
pending on developmental contexts and cell types, DNA
methylation at ICRs is exceedingly stable [1, 6]. The stabil-
ity of this epigenetic mark at ICRs is paramount due to
their control over several imprinted genes within a do-
main that have key roles in cell growth, division, or death
[7–9]. Consistent with this, imprinted genes have gained
much attention as both tumor suppressor genes and on-
cogenes [10–14]. Indeed, epigenetic perturbations within
imprinted domains have been reported in a variety of both
human and mouse malignant neoplasms [15, 16]. How-
ever, the timing in which epigenetic change occurs within
imprinted domains, especially at ICRs, is still unclear.
DNA methylation is an important epigenetic regulator
of gene expression. Misregulation of DNA methylation
in tumor cells is well recognized as an epigenetic
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alteration that results in significant expression level dif-
ferences of genes that contribute to the carcinogenic
process [13, 14, 17–20]. The genome of any given nor-
mal cell by default is virtually stifled with DNA methyla-
tion, with the exception of specific gene promoters and
cis-regulatory elements such as enhancers that contrib-
ute to the expression of genes necessary for the proper
function of the respective cell. However, during carcino-
genesis, the levels of DNA methylation are drastically re-
duced genome wide [21]. There are two distinct drastic
reductions in 5-methylcytosine that occur throughout
the genome during the carcinogenic stages: first, during
the transition of normal cells to immortalized tumor
cells, and second, as benign tumor cells acquire infiltra-
tive capacity [21]. Interestingly, hypermethylation at spe-
cific regulatory elements such as tumor suppressor gene
promoters occurs concomitantly with genome-wide hy-
pomethylation during these critical transitional stages.
Although ICRs have been well identified as targets for
hypermethylation, the functional role that this epigenetic
aberration plays during the carcinogenesis process re-
mains largely uncharacterized [15, 16]. Does hyperme-
thylation at ICRs contribute to the initiation of tumor
formation, the proliferation of tumor cells, or the transi-
tion of a benign process to that of an infiltrative one?
In the current study, we exploited the KrasG12D gen-
omic mutation to initiate carcinogenesis in mice and
surveyed the epigenetic stability at ICRs in two funda-
mentally different neoplasms: squamous papilloma that
remains a benign process but exhibits continual growth,
and T cell lymphoblastic lymphoma that rapidly acquires
infiltrative capacity. This comparison allowed further
characterization of the functional role that aberrant
DNA methylation at ICRs plays during the carcinogenic
process. According to the results, ICRs remain epigenet-
ically stable during the initiation of carcinogenesis and
throughout the growth of tumors. However, DNA hyper-
methylation was observed across virtually all ICRs in
infiltrative tumor cell populations regardless of their
duration. These data suggest ICRs are targeted during
the second phase of DNA methylation alterations to the
genome and epigenetic instability among ICRs contrib-
utes to the infiltrative capacity of tumor cells. Detailed
results and the relevant discussion are presented below.
Results
In this study, we sought to test whether the instability of
DNA methylation at imprinting control regions (ICRs) is
primarily associated with the transition of tumor cells to
more infiltrative states. We also sought to compare the
relative stability of DNA methylation at ICRs with that
of other regulatory sequences such as evolutionarily con-
served regions (ECRs) that are known to be putative en-
hancers and associated with the ICR of their respective
imprinted domain. To accomplish this, we utilized a
floxed allele that contains the oncogenic KrasG12D mu-
tation to initiate tumorigenesis. The LSL-KrasG12D allele
contains a Lox-Stop-Lox (LSL) transcriptional stop cas-
sette within the first intron, and a point mutation in the
second exon that causes a substitution (glycine to aspar-
tic acid) at the 12th amino acid of the KRAS protein
(Fig. 1a) [22, 23]. Upon the activity of cyclic recombinase
(Cre), the stop cassette is removed from the first intron
allowing transcription to proceed and produce a full-
length transcript that encodes the oncogenic KRASG12D
protein.
The KrasG12D mutation is sufficient to initiate both
an infiltrative T cell neoplasm and benign squamous
cell papilloma [15, 24, 25]. Furthermore, the KrasG12D
mutation has also been exploited to study non-small
cell lung cancer, pancreatic cancer, and colorectal tu-
mors. Previously, we reported the epigenetic instability
at ICRs within T cell lymphoma driven by the KrasG12D
mutation, which suggested that ICRs are targeted for
hypermethylation in infiltrative T cell populations [15].
With the current study, we sought to further support the
previous report by comparing the T cell neoplasm to a
benign or non-infiltrative tumor type. To accomplish this,
we bred mice that express Cre under the Mouse Mam-
mary Tumor Virus long terminal repeat promoter
(MMTV-Cre) with the LSL-KrasG12D line to simultan-
eously target oncogenic KrasG12D to T cells and epithelial
cells of the mucous membranes (Fig. 1b) [26, 27]. Using
this breeding scheme, we obtained 80 mice from 11 litters
with an average litter size of 7. Of the 80 total mice, 28
were positive for the recombined KrasG12D allele, which
deviated significantly from the expected Mendelian ratio
(P = 0.007, chi-square). All of the recombinant progeny
developed squamous papilloma and nearly 40% developed
thymic lymphoma as well as squamous papilloma (Fig. 1c,
d) [15]. Unlike the thymic lymphoma, which infiltrated
and extensively replaced the surrounding tissues (Fig. 1e),
the squamous papillomas were benign. The squamous
papilloma lesions retained an exophytic growth pattern
with an overall thickening of the epithelial layer into
finger-like projections (Fig. 1f). In sum, a mouse breeding
scheme utilizing KrasG12D/MMTV-Cre mice was suc-
cessful in obtaining mice that developed both benign and
infiltrative lesions.
DNA methylation at ICRs remained stable with the
50% methylation levels in benign tumor cells, but be-
came unstable with hypermethylation showing greater
than 50% methylation levels in infiltrative T cell tumor
cells (Fig. 2a, b). We sampled 15 squamous papilloma
tumors (7 of which from varying duration were selected
for statistical analyses) and measured the DNA methyla-
tion levels by COmbined Bisulfite Restriction Analysis
COBRA at 11 ICRs, including Igf2r, Zac1, H19, Grb10,
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Ig, Nespas, Peg10, Peg3, Mest, Snrpn, and Rasgrf1 [15,
28–30]. The 15 tumors varied in duration from 1 to
4 months and thus size from small to large. Neverthe-
less, DNA methylation at ICRs remained stable through-
out the growth of all the squamous papilloma tumors.
This was apparent, as the ratio of digested bisulfite PCR
amplicons (representing methylated DNA) to undigested
amplicons (representing unmethylated DNA) in the
tumor samples was not significantly different from the
ratio of normal tissue samples (Fig. 2a, Additional file 1:
Figure S1). We then compared these methylation data in
squamous papilloma to that of thymic lymphoid prolifer-
ative lesions histologically determined to be hyperplastic,
atypical hyperplastic, and neoplastic [15, 31, 32]. While
DNA methylation at ICRs remained stable in hyperplastic
and atypical hyperplastic cells, it became unstable in infil-
trative neoplastic cells (Fig. 2b, c, Additional file 1: Figure
S1). COBRA detected significant DNA hypermethylation
at 9 of the 11 ICRs tested in the infiltrative T cell samples
(C) compared to normal thymus samples (N), including
H19 (C − N = 15%), Grb10 (C − N = 41.6%), Ig
(C − N = 50.2%), Nespas (C − N = 46.5%), Peg10
(C − N = 47.9%), Peg3 (C − N = 47.6%), Mest
(C − N = 52.7%), Snrpn (C − N = 44.9%), and Rasgrf1
(C − N = 40.2%) (Fig. 2b, c). Mean percent methylation




Fig. 1 Targeting oncogenic KrasG12D to mouse T cells and epithelial cells. a Structure of the conditional LSL-KrasG12D allele. Once Cre removes
the transcriptional stop cassette, transcription of oncogenic KrasG12D proceeds. b Breeding scheme involving mouse lines LSL-KrasG12D and
MMTV-Cre. The numbers in parentheses indicate how many pups were born in each litter, the red number indicates the average litter size, and
the blue numbers indicate how many mutant mice were obtained out of the expected number based on Mendelian inheritance. c Gross image
of a thymic T cell lymphoma that is markedly expanding the anterior mediastinum in a KrasG12D mouse. d Gross image of a squamous papilloma
in and around the mouth of a KrasG12D mouse. e Histological image of a thymic T cell lymphoma in a KrasG12D mouse with neoplastic lymphoid
cells completely effacing the normal architecture of the thymus and surrounding mediastinal soft tissue (200× magnification). f Histological image of a
squamous papilloma in a KrasG12D mouse showing the proliferated epithelium forming multiple finger-like projections with maintenance of the tissue
boundaries (100× magnification)
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locus are summarized in Additional file 2: Table S1.
To validate the results from COBRA, we performed
bisulfite sequencing of the Peg3-ICR (Fig. 3). The se-
quencing results were in agreement with those from
COBRA with respect to overall DNA methylation
levels. However, the sequencing profiles do reveal a
mosaic pattern of DNA methylation among the CpG
sites in the tumor samples compared to the normal
sample that showed a clear division between methyl-
ated strands and unmethylated strands. In sum, the
stability of DNA methylation at ICRs displayed a
major difference between tumor cells of different
states, benign versus infiltrative.
Certain regulatory sequence elements within imprinted
domains became epigenetically unstable in the nonmalig-
nant setting. We surveyed the DNA methylation status of
various regulatory sequence elements (ICRs, somatic dif-
ferentially methylated regions (DMRs), ECRs, and pro-
moters) within three imprinted domains (Peg3, Grb10,
and H19) to compare the epigenetic stability of the ICRs
to other sequence elements within their respective
imprinted domains (Fig. 4a–c). We found that there was
no clear trend as to which type of sequence element first
experiences epigenetic change; rather, certain sequence
elements experienced significant changes in DNA methy-
lation in the benign squamous papilloma lesions. Specific-
ally, the Zim3/Zfp264 promoter of the Peg3 domain
became significantly hypermethylated in 5 out of 15 tu-
mors (Additional file 3: Figure S2, Additional file 4: Figure
S3), whereas the ICR and ECR18 of the Peg3 domain
showed no significant change in DNA methylation (Fig.
4a, Additional file 4: Figure S3). On the contrary, the
ECR1 of the H19/Igf2 domain became significantly hyper-
methylated in 2 out of 15 tumors (Additional file 3: Figure
S2, Additional file 4: Figure S3), whereas none of the other
sequence elements in the domain showed significant
change in DNA methylation (Fig. 4c, Additional file 4:




Fig. 2 DNA methylation signatures at ICRs in benign squamous papilloma and infiltrative thymic T cell lymphoma. a Mean percent methylation
with 95% confidence intervals from 11 ICRs in squamous papilloma generated by COBRA. Data from 7 out of the 15 squamous papilloma tumors
are shown and compared to a normal sample denoted with an N. b Mean percent methylation with 95% confidence intervals from 11 ICRs in
thymic lymphoma generated by COBRA. Data from 3 representative thymic lymphoma samples (A—hyperplastic, B—atypical hyperplastic, and
C—neoplastic) are compared to normal thymus tissues labeled N. c Summary of DNA methylation changes at the 11 ICRs in papilloma and
thymoma. Red represents significant hypermethylation based on the samples having a P value less than 0.05, and gray represents no significant
DNA methylation changes detected
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Peg3 and H19/Igf2 domains experienced significant
changes in DNA methylation, all sequence elements in the
Grb10 domain remains stable in all squamous papilloma
lesions (Fig. 4b, Additional file 4: Figure S3). Mean percent
methylation values with 95% CIs for each locus are
summarized in Additional file 4: Figure S3. In sum, the
DNA methylation at all four elements tested, ICRs, DMRs,
promoters, and ECRs, behave similarly during carcinogen-
esis, although some elements are affected earlier than
others in individual cases.
Fig. 3 Bisulfite sequencing of the Peg3 imprinting control region. Each row represents an individual sequencing result from a clone. Each column
represents a CpG site within the Peg3-ICR PCR product. The black boxes denote methylated CpG cites. The white boxes denote unmethylated CpG
sites. The restriction enzyme digestion sites within the PCR products are marked with triangles: purple for HphI and red for TaqαI. Red coloration of the
sample name/number indicates significant methylation changes detected by both COBRA and sequencing
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Discussion
Many efforts have been focused on determining the po-
tential role that imprinted genes may play during carcino-
genesis [10, 11, 15, 16, 21, 33, 34]. Analyses of human
malignant neoplasms have revealed that many ICRs and
putative enhancers within imprinted domains show sig-
nificant epigenetic change pertaining to DNA methyla-
tion and that these changes often correlate with the
expression level differences of nearby imprinted genes
within the domain [16]. However, the question whether
this epigenetic instability within imprinted domains
contributes to the infiltration potential of tumor cells
remains elusive [15]. In the current study, we initiated
tumorigenesis in mice with the KrasG12D mutation
and subsequently compared the epigenetic stability of
various regulatory sequence elements within imprinted
domains between two fundamentally different neoplasms,
benign squamous papilloma, and malignant T cell lymph-
oma. Although there is some overlap with our previous




Fig. 4 DNA methylation signatures of various sequence elements within imprinted domains in squamous papilloma and thymoma. a Peg3
domain structure. Sequence elements analyzed include Zim2—differentially methylated region (DMR), Zim1 promoter, APeg3 promoter,
Peg3—imprinting control region (ICR), ECR18, and Zim3/Zfp264—DMR. b Grb10 domain structure. Sequence elements analyzed include
Ddc—promoter, ECR154, Grb10—ICR, Grb10 promoter, and Cob1 promoter. c H19/Igf2 domain structure. Sequence elements analyzed include
ECR2, H19 promoter, H19—ICR, ECR1, and Igf2—DMR. All sequence elements are listed in order as they appear in the figure from left to right
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report that there is a stark contrast in the epigenetic sta-
bility at ICRs between the benign and infiltrative lesions
studied: while DNA methylation among ICRs was stable
in the benign lesions, including in the thymic lymphoid
hyperplastic lesions, it was highly unstable in the infiltra-
tive thymic T cell lesions. The epigenetic instability at im-
printing control regions was also seen in our previous
report on the infiltrative thymic lymphoma, which were
isolated from mice using a different breeding scheme in-
volving a conditional knockout construct for Peg3 that
was bred into the KrasG12D model. Thus, it should be
noted that even though the tumors from each study were
isolated from mice of two different breeding schemes, the
thymic tumors in both studies were of the same genotype
(MMTV-Cre/KrasG12D). We also expanded our analysis
of imprinted domains in the current study and show that
DNA methylation is unstable at certain regulatory se-
quence elements specific to their imprinted domain in
both the benign and malignant lesions. Overall, it appears
that imprinted domains are most vulnerable to epigenetic
change in infiltrative tumor cells.
DNA methylation settings at ICRs are critical for main-
taining parent-of-origin specific expression of many genes
within an imprinted domain [4]. ICRs contain various se-
quence elements that commonly manifest aberrant DNA
methylation trends in tumor cells [18]; thus, the stability
of DNA methylation at ICRs is concerning in the context
of carcinogenesis. Moreover, ICRs are susceptible to the
Knudson two-hit hypothesis because one allele is already
methylated and silenced in the native state. Therefore,
ICRs can potentially respond to either hypomethylation
events or hypermethylation events. Indeed, the Knudson
two-hit hypothesis has been well supported with hyperme-
thylation of imprinted genes in malignant tumors [13, 15,
16]. However, the timing when ICRs manifest epigenetic
change, particularly DNA methylation changes, is debat-
able. First, do epigenetic changes at ICRs coincide with
the initiation of carcinogenesis or, second, do epigenetic
changes at ICRs coincide with neoplastic transformation
of tumor cells?
According to the results of our analyses of the squa-
mous papillomas, DNA methylation at ICRs remained
stable throughout the duration of these benign tumors
(Fig. 2). This suggests that epigenetic instability at ICRs
is not associated with the early events of carcinogenesis.
However, this epigenetic stability is particularly intri-
guing given that two genome-wide DNA demethylation
events take place in mouse skin carcinogenesis: first,
during transition from immortalized non-tumorigenic
keratinocytes to benign papilloma cells and, second, dur-
ing transition from epithelial to spindle cells, which is
associated with a sharp increase in infiltrative potential
(Fig. 5) [21]. Moreover, these genome-wide reductions in
5-methylcytosine are accompanied by two waves of
DNA hypermethylation at specific tumor suppressor
gene promoters [21]. Unfortunately, we were unable to
analyze the epigenetic activity at ICRs during the second
wave of DNA methylation changes in the squamous pap-
illoma panel as these epithelial cells did not undergo the
epithelial-mesenchymal transition. Furthermore, these
squamous tumors did not even advance to squamous
cell carcinomas. Nevertheless, the epigenetic stability at
ICRs throughout the first reconstruction of the epige-
nome suggests imprinted genes do not have a role in the
initiation of carcinogenesis.
Epigenetic stability at ICRs is challenged during the
second reconstruction of the DNA methylome (Fig. 5).
This wave of DNA methylation changes is associated
with increase in the infiltrative potential of tumor cells.
This is demonstrated by the results from the T cell
lymphoblastic lymphoma panel (Fig. 2). In addition to
neoplastic thymic lymphoid lesions, this panel also in-
cluded hyperplastic and preneoplastic thymic lymphoid
lesions [15]. ICRs remained epigenetically stable in the
a b
Fig. 5 DNA methylation trends during carcinogenesis. a The genome-wide reductions in 5-methylcytosine during the transition of normal cells to
benign tumor cells (first hash mark) and when benign cells gain infiltrative potential (second hash mark). b Specific hypermethylation events that
coincide with the genome-wide hypomethylation trends. The red line represents hypermethylation at tumor suppressor gene (TSG) promoters
and the blue line represents hypermethylation at imprinting control regions (ICRs)
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hyperplastic and preneoplastic specimens regardless of
the duration of the lesions. In contrast, malignant neo-
plastic specimens displayed marked epigenetic instability
with nearly all the ICRs becoming hypermethylated, re-
gardless of the duration of the lesion. ICRs acquiring
hypermethylation do not necessarily confer repression of
imprinted genes as seen with hypermethylation in tumor
suppressor gene promoters [33]. For instance, hyperme-
thylation at the ICR of the H19/Igf2 domain can poten-
tially result in complete repression of H19 and bi-allelic
expression of Igf2, a known oncogene, whereas hyperme-
thylation at the ICR of the Peg3 domain can potentially
result in repression of Peg3, a putative tumor suppressor
[5]. Thus, concomitant hits to multiple ICRs can simul-
taneously activate oncogenes while suppressing tumor
suppressor genes. Overall, it appears ICRs are targeted
to be hypermethylated in the midst of the second drastic
genome-wide reduction in 5-methylcytosine, a hallmark
of tumor progression to malignant disease. This raises
the notion that epigenetic instability among ICRs could
enhance the infiltrative capacity of tumor cells.
The epigenetic stability among the ICRs in the benign
tumors is not a common theme among other regulatory
sequences within their respective imprinted domain. This
is demonstrated by our analysis of the H19/Igf2 and Peg3
imprinted domains (Fig. 4). For instance, the Zfp264
promoter within the Peg3 imprinted domain became
hypermethylated in several benign specimens while the
ICR retained normal DNA methylation patterns. This
observation demonstrates the specificity of DNA methyla-
tion changes among sequence elements within imprinted
domains during tumor progression. The observed spe-
cificity of DNA methylation changes within a single
imprinted domain further supports the notion that
epigenetic changes at ICRs could potentially be in-
volved in enhancing the infiltrative potential of tumor
cells as ICRs are only targeted during the second re-
construction of the DNA methylome.
There are limitations to consider with the methodology
used to measure DNA methylation for the current study.
First, COBRA is not a very sensitive method and it only
measures the methylation at one CpG site at a time.
Although densitometry can be performed to quantify
COBRA data as we did in the current study, COBRA is
also inherently qualitative. To address these issues and to
validate the results from COBRA, we performed bisulfite
sequencing of the Peg3 bisulfite PCR products. The results
from sequencing reinforced the results from COBRA;
however, there are also limitations to consider with trad-
itional bisulfite sequencing due to the low number of
reads compared to Mass Array or Next Generation se-
quencing approaches. Again, caution should be used
when interpreting the results from bisulfite sequencing,
as they are more qualitative than quantitative. For
studies that require more quantitative methodologies
such as in the case with human cancer studies, it is
advised to employ more sensitive methods that utilize
mass array and/or next generation-based sequencing
technology.
Conclusion
To our knowledge, this is the first study to compare the
epigenetic stability among ICRs between benign and
malignant tumor cells driven by the same genomic muta-
tion, KrasG12D. The results from the DNA methylation
analyses of this study demonstrate that ICRs remain stable
during the first reconstruction of the DNA methylation
landscape but are targeted specifically by DNA hyperme-
thylation during the second reconstruction of the DNA
methylation landscape—a hallmark that defines the transi-
tion of benign tumor cells to malignant. Further investiga-
tion is required to determine whether the observed
changes in DNA methylation at ICRs directly enhance the
infiltrative potential of tumor cells. However, considering
the effects that aberrant DNA methylation at an ICR can
have on an entire imprinted domain, it is likely that con-
comitant hits to several ICRs can result in an aberrant
protein environment within a tumor cell whereby several
tumor suppressors are shut down and several oncogenes
are activated. These dynamic changes in critical imprinted
gene products may very well enhance a tumor cell’s ability
to infiltrate tissue boundaries. Lastly, monitoring DNA
methylation at ICRs may be a useful diagnostic in the clin-
ical setting in determining the progression of a neoplasm.
Methods
Mouse strains and breeding
Two mouse strains were purchased from Jackson
laboratories: B6.129-Krastm4Tyj/Nci (LSL- KrasG12D)
and STOCK Tg(MMTV-Cre)4Mam/J (MMTV-Cre) [22,
23]. The LSL-KrasG12D mice were maintained as het-
erozygotes and bred with homozygous MMTV-Cre mice.
Genotyping
Mice weaned at 21 days postpartum were separated by
sex and marked by a hole punch with varying positions
in the left ear. Ear clips were taken from the right ear
for genomic DNA isolation and subsequent PCR ana-
lysis. Sample preparation and PCR protocols have been
previously described [15]. Primer sets for genotyping
can be found in Additional file 5: Table S2.
Necropsy and histopathology
Mice were monitored daily for signs of distress or weight
loss equaling 15% of total body weight and sacrificed
according to the guidelines set forth in the IACUC proto-
col #16–060. Upon euthanasia, mice were submitted to
full necropsy. Samples of squamous papilloma and thymic
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lesions were placed directly in tail lysis buffer with Pro-
teinase K for subsequent DNA isolation. Detailed buffer
compositions and DNA extraction protocols were pre-
viously reported [15]. The remaining portion of these
lesions and representative samples of all other tissues
were fixed for at least 48 h in 10% neutral buffered for-
malin (Thermo Scientific, Cat. # 5725) and then trans-
ferred to 70% ethanol. Tissues were further processed
according to standard protocols for hematoxylin and
eosin (H&E) staining and examined by a board-certified
pathologist (IML).
DNA methylation analysis
Combined Bisulfite Restriction Analysis (COBRA) and bi-
sulfite sequencing was performed for DNA methylation
analyses [28]. Genomic DNA from the thymic lymphoma
and squamous papilloma lesions was isolated using a
commercial kit (Genomic DNA clean and concentrator-
25, Zymo Research, Cat. No. D4065), and subsequently,
bisulfite-converted using another commercial kit (EZ
DNA methylation kit, Zymo Research, Cat. No. D5002).
Bisulfite-converted DNA was then used as template for
PCR. Additional file 5: Table S2 contains detailed infor-
mation pertaining to the genomic locations analyzed
and their respective oligonucleotide bisulfite PCR pri-
mer sets. Each bisulfite PCR product was digested with
at least one restriction enzyme. The resulting fragments
were visualized using gel electrophoresis, and band
densities were calculates as described below. Images
were exported as tiff files into ImageJ software. Briefly,
data was inverted, the background was removed, the
brightness/contrast was adjusted, the bands were se-
lected using the rectangular tool to generate density
plots, density peaks were gated using the line tool, and
the area of each peak was then calculated using the
wand tool. The results were then copied into a Micro-
soft Excel spreadsheet for further processing and statis-
tics. DNA methylation values were calculated in the
following manner: 100*((area of peak from digested
DNA/s)/(area of peak from digested band/s + area of
peak from undigested DNA)). These % methylation
values were then used for statistical analyses. First, a
single factor ANOVA test was performed to identify
significant differences among the sample. Upon a sig-
nificant P value from ANOVA, the means of the tumor
samples were then compared to the normal sample using
the Student t test (two sample assuming equal variance).
Three independent technical replicates were performed
for each sample and each primer set. For the squamous
papilloma panel, 15 samples were analyzed initially;
however, only seven samples were used for statistical com-
parisons based on the consistent results from successful
bisulfite PCRs across all primer sets (Additional file 6:
Table S3). For bisulfite sequencing, PCR products were
individually cloned using a commercial vector system
(pGEM®-T Easy Vector System I, Promega, A1360). Ten
clones were selected for sequencing. In brief, plasmids
were purified using a commercial kit (DNA-spin plasmid
DNA purification kit, iNtRON Biotechnology, 17097), re-
striction digest was performed to check for insert, BigDye
Terminator v3.1 reactions were performed, products were
precipitated and re-suspended in ABI Hi-Di formamide
and sequences using a 3130XL Genetic Analyzer. Sequen-
cing results were then manually processed to remove vec-
tor sequence, placed in the same orientation, and aligned
using ClustalW. The methylation of each CpG site in the
sequencing reads was then manually scored in an Excel
spreadsheet. Sequencing reads with less than 95% bisulfite
conversion efficiency were removed.
Additional files
Additional file 1: Figure S1. DNA methylation signatures at ICRs in
benign squamous papilloma and infiltrative thymic T cell lymphoma.
Representative DNA methylation data from 11 ICRs in squamous
papilloma and thymic lymphoma generated by COBRA. Data from 7 out
of the 15 squamous papilloma tumors are shown and compared to a
normal sample denoted with an N. Data from 3 representative thymic
lymphoma samples are shown: A – hyperplastic, B – atypical hyperplastic,
and C – neoplastic. The red C denotes where hypermethylation at ICRs
occurred. Unmethylated DNA is denoted with a blue U, and methylated
DNA is denoted with a red M. (PDF 26309 kb)
Additional file 2: Table S1. Mean percent methylation with 95%
confidence intervals for each locus and sample. (XLSX 67 kb)
Additional file 3: Figure S2. Representative COBRA data from the H19
– ECR1 and the Zim3/Zfp264 – promoter. Squamous papilloma samples
are numbered 1–15 and compared to a sample of normal skin (N). The
numbers underneath the gel images indicate percent methylation for
each sample. Red numbers indicate the samples that showed significant
DNA methylation change based on P values less than 0.05. Unmethylated
DNA is denoted with a blue U and methylated DNA is denoted by a red
M. (PDF 5050 kb)
Additional file 4: Figure S3. Methylation profiles of ICRs, DMRs,
promoters, and ECRs within three imprinted domains from squamous
papilloma and thymic lymphoma tumors. Seven squamous papilloma
tumors samples (labeled 1–7) from oral mucosa are compared to normal
oral mucosa tissue (labeled N) from a wild-type littermate. Three thymic
lymphoma tumor samples (A – hyperplastic, B – atypical hyperplastic,
and C – neoplastic) are compared to normal thymic tissue (labeled N)
isolated from a wild-type littermate. Mean percent methylation from
three technical trials is plotted on the y-axis with 95% confidence
intervals. Sample legends are presented at the bottom of the figure.
(PDF 577 kb)
Additional file 5: Table S2. Genomic locations analyzed. This table
contains the bisulfite PCR primer sets used along with the restriction
enzyme used for each PCR product. (XLSX 17 kb)
Additional file 6: Table S3. This table contains the quantified COBRA
data and statistical analyses for each locus analyzed. (XLSX 300 kb)
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